We demonstrate a novel role of phospholipase D in M1-dependent rodent cortical plasticity and M1 PAMs that do not couple to phospholipase D have functionally distinct effects on cortical plasticity than non-biased M1 PAMs.
Introduction
The M1 muscarinic acetylcholine receptor (mAChR) has attracted intense interest as a promising therapeutic target for the treatment of the cognitive disruptions in schizophrenia and Alzheimer's disease (AD). M1 is highly expressed across many forebrain regions implicated in the pathophysiology of schizophrenia and AD, including the cortex, striatum, and hippocampus (1, 2). Interestingly, dysregulation of the M1 receptor has been reported within a subset of patients suffering from schizophrenia illustrated by a dramatic reduction of M1 receptor expression in pyramidal neurons in cortical regions highly implicated in complex behaviors such as cognition and working memory (3, 4) . Furthermore, cholinesterase inhibitors, which boost overall cholinergic tone, provide some efficacy in patients with AD; however, doselimiting adverse effects typically occur with disease progression. Therefore, selectively enhancing M1 signaling may provide a potential therapeutic approach for the treatment of the cognitive deficits associated with AD and schizophrenia.
Several orthosteric mAChR agonists, including the nonselective mAChR partial agonist xanomeline (5) , have entered clinical trials as potential cognition-enhancing agents.
Unfortunately, xanomeline failed to meet significant cognition enhancement end points, a result attributed to dose-limiting nonselective cholinergic agonist adverse effects hypothesized to be mediated by the activation of peripheral M2 and M3 receptors (6) (7) (8) (9) . To increase selectivity for M1 and therefore minimize nonselective adverse effects, multiple research efforts shifted to developing compounds that act via allosteric sites on mAChRs, which are structurally distinct from the orthosteric binding site and may be less highly conserved among receptor subtypes. To date, we and others have identified highly subtype-selective positive allosteric modulators (PAMs) of the M1 receptor that avoid activation of other mAChR subtypes (see reviews (10) (11) (12) ). Importantly, M1 PAMs have shown robust efficacy in enhancing cognition and rescuing cognitive deficits in preclinical animal models relevant for AD and schizophrenia (13) (14) (15) (16) (17) (18) .
While these preclinical findings are extremely promising for the potential of M1 PAMs to reverse cognitive deficits in patients, M1 PAMs can display a diverse range of pharmacological properties, some of which are potentially detrimental to in vivo efficacy. Previously, we found that the presence of allosteric agonist activity in M1 PAMs can limit in vivo efficacy and increase adverse effect liability (13, 14, 19, 20) . Thus, minimalizing agonist activity can maximize the therapeutic window of M1 PAMs (13, (19) (20) (21) . These previous studies demonstrate that a complete understanding of the different pharmacological properties of structurally distinct M1 PAMs is essential to fully evaluate clinical candidates and maximize their therapeutic potential.
In addition to displaying differences in allosteric agonist versus pure PAM activity, M1 PAMs can also differ in their ability to confer bias to M1 signaling. Signal bias is the phenomenon in which different GPCR ligands induce unique active receptor-complex states that are biased toward specific signaling pathways (22) . For instance, characterization of a broad range of structurally diverse M1 PAMs revealed that some M1 PAMs potentiate M1 signaling through the canonical phospholipase C (PLC) pathway but do not potentiate M1-mediated activation of another phospholipase, phospholipase D (PLD) (23) . PLD is a widely expressed enzyme that hydrolyzes the major membrane phospholipid phosphatidylcholine into the signaling molecules phosphatidic acid (PA) and choline (24) . PLD can be activated by a variety of receptors, including the M1 receptor (25, 26) . While there are six distinct mammalian isoforms of PLD, only PLD1 and PLD2 have well established enzymatic activity within the CNS (24, 27) . However, little is known about the roles of PLD in regulating brain function, and the potential roles of PLD in M1-dependent signaling has not been explored. Thus, it is unclear whether M1 PAMs that do not activate coupling of M1 to PLD in cell lines will display functional differences in regulating M1 signaling in the CNS relative to non-biased M1 PAMs. For other GPCRs, signal bias provides the exciting potential advantage of selectively activating or potentiating therapeutically relevant pathways while minimizing activation of pathways responsible for adverse effects (11, 28, 29) . Therefore, a better understanding of these signaling mechanisms is essential for the development of M1 PAMs as potential therapeutics for the treatment of prevalent cognitive disorders.
We now report that PLD activity is necessary for a form of M1-dependent long-term depression (LTD) in the prefrontal cortex (PFC) that has previously been implicated in the potential therapeutic response to M1 PAMs (14, 30, 31) . Furthermore, biased M1 PAMs that do not potentiate M1 coupling to PLD fail to potentiate this form of LTD, but actively inhibit M1dependent LTD at this synapse. In contrast, biased and non-biased M1 PAMs function similarly in their ability to potentiate M1-dependent responses in the CNS that we found to be PLDindependent. Together, these studies reveal that PLD is a critical downstream signaling node for this M1-dependent LTD in the PFC and demonstrate that biased M1 PAMs can have fundamentally different effects, relative to those of non-biased M1 PAMs, in regulating specific aspects of CNS function.
Results

M1 activation leads to phospholipase D activity in hM1-CHO cells
M1 activation has previously been shown to lead to an increase in PLD activity (25, 26) , but it is not known whether this reflects activation of PLD1, PLD2, or both isoforms. Therefore, we set out to characterize the relative contribution of the two distinct PLD isoforms on selective activation of M1 in Chinese Hamster Ovary (CHO) cells stably expressing the M1 receptor. While direct measurement of the PLD product PA is challenging due to its rapid conversion into other lipids such as diacylglycerol and lysophosphatidic acid, in the presence of a primary alcohol such as 1-butanol, PLD generates the stable product phosphatidylbutanol (pButanol). pButanol cannot be metabolized, therefore allowing for quantification of intracellular PLD activity (24, 32, 33) . In agreement with previous findings (23), the cholinergic orthosteric agonist carbachol (CCh) induces a robust increase in pButanol accumulation that is blocked by the selective M1 antagonist VU0255035 (34) ( Fig. 1A) . Furthermore, the PLD1,2 inhibitor ML299 (35) potently blocks M1-mediated pButanol production, thereby validating that PLD is responsible for the generation of pButanol. Using the recently developed PLD1 (VU0359595) (36) and PLD2 (VU0364739) (37) isoform-selective inhibitors, we report that pharmacological inhibition of PLD1, but not PLD2, blocks M1-dependent activation of PLD in this in vitro assay (Fig. 1A) . These data reveal that in this cell-based assay, M1-dependent activation of PLD primarily occurs through PLD1, not PLD2.
While we have previously characterized M1 PAMs that couple to PLC but not PLD (23), these early biased M1 PAMs suffer from low potency and aqueous solubility. Therefore, we set out to develop additional M1 PAMs that potentiate M1 coupling to PLC, but do not potentiate coupling to PLD. Previously, we have reported the M1 PAMs VU0453595 (half-maximal effective concentration (EC50) 2140 ± 440 nM), VU0405652 (EC50 2580 ± 440 nM) and VU0405645 (EC50 340 ± 30 nM) are potent M1 PAMs with respect to their ability to potentiate calcium mobilization in CHO cells stably expressing the M1 receptor ( Fig. 1B,C) (30, 38) . We now report, unlike the prototypical M1 PAM VU0453595, that both VU0405652 and VU0405645 fail to potentiate CCh activation of PLD in this in vitro assay ( Fig. 1D ). These findings demonstrate that VU0405652 and VU0405645 but not VU0453595 are biased M1 PAMs in that they do not potentiate M1 coupling to PLD.
PLD1 but not PLD2 is required for M1-mediated LTD in the mPFC
From the cell-based assay we know that M1 activation can increase PLD activity; however, little is known about whether PLD is necessary for M1-dependent responses in native neuronal tissue. Therefore, we set out to characterize the role of PLD in mediating established responses to M1 activation in CNS preparations. One response to M1 activation that may be relevant to some aspects of cognitive function is induction of long-term depression (LTD) of excitatory synaptic transmission in the medial prefrontal cortex (mPFC) (13, 14, 19, 30, 31, 39) . We assessed the role of PLD in inducing LTD in the mPFC by measuring changes in layer V field excitatory postsynaptic potentials (fEPSP) evoked by electrical stimulation of afferents in layer II/III of the mPFC ( Fig. 2A ). Consistent with previous findings (13, 14, 30, 39) , a maximal concentration of CCh induces robust LTD of fEPSP slope at this synapse ( Fig. 2B ). Interestingly, bath application of the PLD1,2 inhibitor ML299 before and during CCh application led to a complete loss of CChinduced LTD (Fig. 2C, F) . Using selective inhibitors for each PLD isoform, we found that pharmacological inhibition of PLD1 with VU0359595 fully blocked CCh-induced LTD (Fig 2D, F) .
Congruent with the cell-based assay findings, inhibition of PLD2 with VU0364739 had no effect on CCh-induced LTD at this synapse ( Fig. 2E , F).
To confirm these pharmacological results, we obtained PLD1 knockout (KO) mice. In agreement with the pharmacological findings, CCh induces a robust LTD in the littermate controls but not the PLD1 KO mice ( Fig. 2G, H) . Importantly, the ability of a selective agonist of group II metabotropic glutamate receptors (LY379268) to induce LTD was intact in the PLD1 KO mice and not significantly different than littermate controls ( Fig. I, J ). This form of LTD has been previously characterized in detail and is mechanistically distinct from M1-dependent LTD in the mPFC (40) (41) (42) . These data suggest that the loss of M1-mediated LTD is not due to a general deficit in LTD in this brain region. Taken together, these data demonstrate a critical role of PLD, specifically PLD1, in this form of cortical M1-LTD.
Biased M1 PAMs fail to potentiate M1-LTD in the mPFC
We next tested the hypothesis that biased and non-biased M1 PAMs would display functional differences in their ability to potentiate this PLD-dependent CCh-induced LTD of layer V fEPSPs electrically evoked in layer II/III in the mPFC. As previously shown, a submaximal concentration of CCh (10 µM) does not induce LTD at this synapse ( Fig. 3A) (13, 19, 30) . Similar to previous findings, bath application of the non-biased M1 PAM VU0453595 for 10 min before and during CCh application leads to a robust LTD ( Theoretically, M1 PAMs that confer this form of biased M1 signaling stabilize a conformation of M1 that favors activation of signaling by PLC and not PLD (43) (44) (45) (46) . Based on this, if these PAMs confer true bias to M1 signaling, they should inhibit PLD-mediated responses.
Thus, we tested the hypothesis that PAMs that bias M1 signaling away from PLD would therefore block the LTD normally induced by a maximal concentration of CCh (Fig. 3F ). In agreement with our hypothesis, VU0405645 blocked CCh-induced LTD (Fig. 3F, G) . Collectively, these findings demonstrate a novel role of PLD in this cortical M1-LTD and that biased M1 PAMs not only fail to potentiate a submaximal concentration of CCh-LTD, but can also actively block a maximal concentration of CCh-LTD.
PLD is not necessary for the M1-dependent increase of layer V sEPSC in the mPFC
In light of these findings, we next set out to determine whether PLD is important in other M1-dependent functions in the CNS. Previously, we reported that M1 activation increases the frequency of spontaneous excitatory postsynaptic currents (sEPSC) in mPFC layer V pyramidal neurons (15, 19, 30) . In agreement with these previous findings, bath application of a maximal concentration of CCh induces a robust increase in sEPSC frequency in layer V pyramidal neurons ( Fig. 4A) . In contrast to M1-dependent LTD, the effect of CCh on sEPSCs was unchanged by pretreatment and co-application of the dual PLD inhibitor ML299 (Fig. 4B ). Quantification of the peak CCh effect on sEPSC frequency indicates no statistically significant difference between CCh alone and CCh in the presence of ML299 (Fig. 4C ). These data suggest that PLD is not necessary for this M1-dependent increase of sEPSC frequency in mPFC layer V pyramidal neurons.
Next, we sought to compare the two biased M1 PAMs, VU0405652 and VU0405645, to our prototypical M1 PAM, VU0453595, in their ability to potentiate a submaximal concentration of CCh-induced increases in mPFC layer V pyramidal neuron sEPSC frequency. As expected, bath application of a submaximal concentration of CCh did not induce a significant change in sEPSC frequency ( Fig. 4D ). Similar to the M1 PAM BQCA (15) , the non-biased M1 PAM VU0453595 induces a robust potentiation of the effect of a submaximal concentration of CCh on sEPSC frequency (Fig. 4E) . Consistent with the studies with PLD inhibitors, both VU0405652 ( Fig. 4F) and VU0405645 (Fig. 4G ) potentiate agonist-induced increases in sEPSC frequency.
Quantification of the peak effect on sEPSC frequency indicates a statistically significant difference between CCh alone and all three M1 PAMs (Fig. 4H ). Therefore, both biased and non-biased M1
PAMs function similarly in their ability to potentiate a submaximal concentration of agonistinduced increases in mPFC layer V pyramidal neuron sEPSC frequency ( Fig. 4I ).
PLD is not necessary for M1 effects on excitability of striatal SPNs.
The M1 receptor is also highly expressed in the striatum (47), and we have shown that M1 activation in spiny projection neurons (SPN) in the dorsal lateral striatum leads to a robust increase in SPN excitability that can be blocked by a selective M1 antagonist (48, 49) . Therefore, we set out to determine whether PLD is required for this M1-dependent response. As expected, bath application of CCh induces a robust increase in dorsal lateral striatum SPN excitability ( Fig.   5A ). In the presence of the dual PLD inhibitor ML299, CCh is still able to induce a marked increase in SPN excitability compared to baseline ( Fig. 5B ). Quantification of the CCh-induced increase in SPN excitability showed no significant difference between the change in number of spikes per pulse between control (DMSO) and ML299 groups (Fig. 5C ). Therefore, similar to the sEPSC findings, PLD is not necessary for M1-dependent increases in dorsal lateral SPN excitability.
The finding that PLD is not involved in M1 regulation of SPN excitability suggests that biased M1 PAMs that selectively potentiate coupling to PLC and do not potentiate PLD activity would function similarly to non-biased M1 PAMs in their ability to potentiate responses to a low concentration of CCh on SPN excitability. In agreement with our previous findings (49), a submaximal concentration of CCh induces a minimal increase in SPN excitability (Fig. 5D ) that can be robustly potentiated by the prototypical M1 PAM VU0453595 (Fig. 5E ). As expected, both VU0405652 ( Fig. 5F) and VU0405645 (Fig. 5G ) potentiate a submaximal concentration of CChinduced increase of SPN excitability. The maximal increase in the number of spike discharges during agonist application was significantly higher in the presence of each of the three M1 PAMs compared to the DMSO control condition (Fig. 5H-I) . Taken together, these results demonstrate that biased and non-biased M1 PAMs function similarly in their ability to potentiate M1-dependent CNS responses that are PLD-independent.
Discussion
A large body of clinical and preclinical research suggests that enhancing mAChR signaling can be efficacious in the treatment of the cognitive symptoms associated with Alzheimer's disease and schizophrenia (7, 8, 50, 51) . While multiple mAChR subtypes are involved in regulation of cognitive function, the majority of preclinical studies point to a dominant role of M1 and suggest that selective modulation of the M1 receptor may provide a therapeutic potential for the treatment of these devastating cognitive symptoms (14, 15, 17-19, 30, 52-58) . However, M1 regulates CNS function by actions on multiple signaling pathways and M1 PAMs can display a strikingly diverse range of pharmacological properties, including signal bias. At present, little is known about the specific signaling pathways involved in the different physiological effects of M1 activation and how signal bias can affect PAM modulation of M1 actions in identified brain circuits. The present studies provide a fundamental advance in our understanding of at least one novel mechanism by which M1 activation leads to plasticity changes within a key cortical structure in the CNS. Specifically, we found that a previously described M1-dependent LTD in the cortex is dependent on activation of PLD. Furthermore, we identified novel M1 PAMs that selectively enhance M1 coupling to PLC but not PLD, and found that these biased M1 PAMs fail to potentiate this form of M1-dependent LTD. Finally, these biased M1 PAMs actively block the ability of mAChR agonists to induce this PLD-dependent LTD, consistent with the hypothesis that these PAMs stabilize a conformation of M1 that favors activation of PLC over PLD and thereby bias M1 signaling in favor of PLC-mediated responses. Importantly, not all M1-dependent responses are PLD-dependent and biased M1 PAMs function similarly to non-biased M1 PAMs in M1 signaling that is PLD-independent.
While the ability of M1 and other GPCRs to activate PLD is well established (59) , little is known about the physiological roles of PLD in regulating CNS function. This has largely been due to the lack of selective inhibitors and other tools that allow systematic studies of PLD-mediated responses. However, the recent discovery of the highly selective PLD inhibitors used here (35) (36) (37) , along with generation of PLD KO mice and biased M1 PAMs reported in the present studies, provided an unprecedented opportunity to determine the roles of PLD in mediating specific responses to M1 activation. With the availability of these new tools, these studies provide the first clear example of a specific physiological role of PLD in mediating a response to GPCR activation in the CNS and reveal a novel role for PLD in the induction of major form of synaptic plasticity in an identified brain circuit. Furthermore, these novel PLD inhibitors include selective inhibitors of PLD1 and PLD2, the major isoforms of PLD expressed in the CNS. These isoform-selective inhibitors, along with PLD1 KO mice, reveal a critical role of PLD1 as the PLD isoform involved in mediating this response to M1 activation. M1-dependent LTD in the mPFC has been extensively studied and has been postulated to play a critical role in regulating specific inputs to the mPFC from the hippocampus and other extrinsic afferents (60) . Cholinergic regulation of these inputs is thought to be important for the regulation of multiple aspects of mPFC function and previous studies suggest that M1 expression and signaling in the mPFC can be impaired in some pathological states that could be relevant for schizophrenia and Alzheimer's disease (3, 14, 30, (61) (62) (63) (64) (65) (66) (67) . However, very few studies have focused on understanding the cellular mechanisms underlying M1-dependent LTD in the PFC.
While the current studies identify PLD1 being critically important in M1-dependent cortical synaptic plasticity, the detailed molecular mechanism by which M1 signals through PLD to induce synaptic plasticity changes in the cortex remains unknown. Rigorous molecular and biochemical studies to elucidate this signaling pathway are necessary to fully understand the signaling cascade responsible for M1-dependent LTD.
The finding that PLD1 is important for this form of synaptic plasticity, coupled with the finding that biased and non-biased M1 PAMs have functionally distinct effects on this response, raises the possibility that different PAMs could have unique profiles in regulating cognitive function or other in vivo responses. It is possible that biased versus non-biased M1 PAMs could induce dramatically different effects on specific behavioral responses, as is the case for biased and nonbiased PAMs of the mGlu5 subtype of metabotropic glutamate (mGlu) receptor (68, 69) . Finally, in future studies, it will also be important to develop an understanding of the precise molecular mechanisms involved in conferring bias for some M1 PAMs. While there are multiple examples of allosteric modulators of GPCRs inducing biased signaling, little is known about the structural basis of biased versus non-biased signaling. Previous studies reveal multiple allosteric binding sites for some GPCRs, which could contribute to different responses to distinct classes of allosteric modulators (70) (71) (72) . However, recent studies suggest that differences in M1 PAM functionality may not be due to binding to different allosteric binding pockets, but that binding of PAMs to a single allosteric site may stabilize different receptor conformational states (73, 74) .
Understanding how allosteric modulators of GPCRs induce their effects will help facilitate the rational design of the next generation of PAMs and NAMs. The next morning, the plating media was carefully aspirated off and the cells were treated for 5 min with DMSO or M1 PAM then 30 min in the presence of 0.3% 1-butanol in serum-free assay media (1 mL media/well) or no butanol serum-free assay media as a negative control and the plates were incubated at 37 o C. 3 H labeling efficiency was measured by subtracting the postlabeling medium from the pre-labeling medium. All pharmacological agent stocks were used at 500 or 1000-fold higher than the final concentration. Immediately after the incubation, 600 µL ice cold acidified methanol (1:1 ratio of 0.1 N HCl to Methanol) was added and the cells were scraped off using a cell scraper and transferred to a 1.5 mL Eppendorf tube. 300 µL room-temperature CHCl3 was then added and the sample which was then vortexed vigorously for approximately 20 seconds. The samples were then spun at 16,000 g for 5 min to separate phases. The bottom lipid phase was removed carefully to ensure no other phases were carried over and transferred to a new 1.5 mL Eppendorf tube. The samples were then dried under N2 gas until all liquid was evaporated. The lipids were then resuspended in 25 µL CHCl3 and immediately spotted onto the TLC plate (Sorbtech, Norcross GA; Cat#2315126C). Non-radioactive lipid standards such as p-Butanol and phosphatidic acid were also spotted on the TLC plate. The TLC tank was prepared by placing chromatography paper 7-inch (H) x 22.5-inch (W) so that it covers approximately 75% of the tank's height. The mobile phase was then added (10 CHCl3: 2 Methanol: 2 Acetic Acid: 4
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Acetone: 1 H20) and allowed to equilibrate for 1 hour before the TLC plate was added and run for 1.5 to 2 hours. The plate was then removed from the tank and allowed to completely dry before imaging using autoradiography film in conjunction with an intensifying screen (BioMax Transcreen LE, Carestream Health) and placed in a -80 o C freezer for 3-5 days. The film was then processed after exposure and quantified using Chemdoc (Biorad). Slices were then transferred to a room temperature holding chamber for 1.0 hour containing ACSF (in mM: 126 NaCl, 1.25 NaH2PO4, 2.5 KCl, 10 D-glucose, 26 NaHCO3, 2 CaCl2, 1 MgSO4) supplemented with 600-µM sodium ascorbate for slice viability. All buffers were continuously bubbled with 95% O2/5% CO2. Subsequently, slices were transferred to a 30-31 ºC submersion recording chamber (Warner Instruments) where they were perfused with ACSF at a rate of 2 mL/min. Recording pipettes were constructed from thin-walled borosilicate capillary glass tubing For the PFC recordings, pyramidal neurons were visualized based on morphology with a 40X water-immersion lens with oblique illumination coupled with an Olympus BX50WI upright microscope (Olympus). After a stable gigaohm seal was formed, light suction was applied to break through the cell membrane and achieve whole-cell access. The access resistance was checked at the beginning and the end of each experiment and neurons with an access resistance of neurons greater than 30 mOhm were not used for analysis. Pyramidal neurons were further identified by their regular spiking pattern following depolarizing current injections induced by a series of 500 ms current steps (−150pA to +100 pA) incremented in +25 pA performed in current clamp mode. Spontaneous EPSCs were recorded at a holding potential of -70 mV (the reversal potential for GABAA channels) and the junction potential was not compensated. The voltage clamp signal was low pass filtered at 5 kHz and digitized at 10 kHz using a Digidata 1322A and acquired using Axon MultiClamp 700B (Molecular Devices, Sunnyvale, CA) and controlled by pClamp 9.2 and Clampex 10.6.2 running on a Dell PC. After a stable baseline was recorded for 5-10 min, test compounds were diluted to the appropriate concentrations in DMSO (<0.1% final) in ACSF and applied to the bath using a peristaltic pump perfusion system. Cumulative probability plots of inter-event-intervals (IEI) were constructed using 2 min episodes of baseline and peak effect during drug application. All sEPSC analyses were performed using MiniAnalysis into layer V so that the recording and stimulating electrodes were parallel to each other. Inputoutput curves were generated to determine the stimulus intensity that produced approximately 70% of the maximum fEPSP slope before each experiment, which was then used as the baseline stimulation. Data were digitized using a Multiclamp 700B, using a sampling rate of 20,000kHz and were filtered at 0.5kHz, with a Digidata 1322A, pClamp 9.2 and Clampex 10.6.2 software (Molecular Devices) running on a Dell PC (Round Rock, TX). All test compounds, with the exception of CCh (Tocris Bioscience, Bristol, UK) which was diluted in H2O, were diluted to the appropriate concentrations in DMSO (<0.1% final) in ACSF and applied to the bath using a peristaltic pump perfusion system. Offline data analysis to calculate fEPSP slope was performed using Clampfit 10.2 (Molecular Devices).
Statistics. Two-tailed Student's t-test and one-way ANOVA with Bonferonni post-tests were used as appropriate. Changes in fEPSP slope before and during drug add (peak effect) was compared using a paired t-test. For all statistical comparisons, the critical p-value was considered to be 0.05.
The numbers of animals to be used for each experiment outlined within the study were determined using a power calculation statistical analysis using the Power and Sample Size Calculation software program available at Vanderbilt University (Dupont and Plummer, PS Controlled Clinical Trials. 18:274 1997) . Animal numbers are based on a power calculation using standard errors from published studies and previous experience to detect >20% difference for each outlined experiment with an 80% power (alpha = 0.05, power = 80%, delta = 0.2, sigma = 0.18). 
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